mass. movers

Aegerion climbs a second straight day

Aegerion’s Juxtapid drug is used to treat cholesterol disease.

Aegerion’s Juxtapid drug is used to treat cholesterol disease.


Aegerion Pharmaceuticals Inc. rose on Tuesday and Wednesday even after it posted a wider net quarterly loss of $18.9 million amid higher expenses. Aegerion raised its revenue expectations for the year to reflect recent results from the launch of its genetic cholesterol-disease drug, Juxtapid, its sole product on the market. Aegerion raised its net revenue expectation to $30 million to $35 million, from earlier guidance of $15 million to $25 million.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of